Pub Date : 2022-06-08DOI: 10.1007/s40629-022-00212-x
Daria Luschkova, Claudia Traidl-Hoffmann, Alika Ludwig MD
The climate crisis poses a major challenge to human health as well as the healthcare system and threatens to jeopardize the medical progress made in recent decades. However, addressing climate change may also be the greatest opportunity for global health in the 21st century. The climate crisis and its consequences, such as rising temperatures, forest fires, floods, droughts, and changes in the quality and quantity of food and water, directly and indirectly affect human physical and mental health. More intense and frequent heat waves and declining air quality have been shown to increase all-cause mortality, especially among the most vulnerable. Climate warming alters existing ecosystems and favors biological invasions by species that better tolerate heat and drought. Pathogen profiles are changing, and the transmission and spread of vector-borne diseases are increasing. The spread of neophytes in Europe, such as ragweed, is creating new pollen sources that increase allergen exposure for allergy sufferers. In addition, the overall milder weather, especially in combination with air pollution and increased CO2 levels, is changing the production and allergenicity of pollen. The phenomenon of thunderstorm asthma is also occurring more frequently. In view of the increasing prevalence of allergic diseases due to climate change, early causal immunomodulatory therapy is therefore all the more important. During a climate consultation, patients can receive individual advice on climate adaptation and resilience and the benefits of CO2 reduction—for their own and the planet’s health. Almost 5% of all greenhouse gas emissions in Europe come from the healthcare sector. It thus has a central responsibility for a climate-neutral and sustainable transformation.
{"title":"Climate change and allergies","authors":"Daria Luschkova, Claudia Traidl-Hoffmann, Alika Ludwig MD","doi":"10.1007/s40629-022-00212-x","DOIUrl":"10.1007/s40629-022-00212-x","url":null,"abstract":"<div><p>The climate crisis poses a major challenge to human health as well as the healthcare system and threatens to jeopardize the medical progress made in recent decades. However, addressing climate change may also be the greatest opportunity for global health in the 21st century. The climate crisis and its consequences, such as rising temperatures, forest fires, floods, droughts, and changes in the quality and quantity of food and water, directly and indirectly affect human physical and mental health. More intense and frequent heat waves and declining air quality have been shown to increase all-cause mortality, especially among the most vulnerable. Climate warming alters existing ecosystems and favors biological invasions by species that better tolerate heat and drought. Pathogen profiles are changing, and the transmission and spread of vector-borne diseases are increasing. The spread of neophytes in Europe, such as ragweed, is creating new pollen sources that increase allergen exposure for allergy sufferers. In addition, the overall milder weather, especially in combination with air pollution and increased CO<sub>2</sub> levels, is changing the production and allergenicity of pollen. The phenomenon of thunderstorm asthma is also occurring more frequently. In view of the increasing prevalence of allergic diseases due to climate change, early causal immunomodulatory therapy is therefore all the more important. During a climate consultation, patients can receive individual advice on climate adaptation and resilience and the benefits of CO<sub>2</sub> reduction—for their own and the planet’s health. Almost 5% of all greenhouse gas emissions in Europe come from the healthcare sector. It thus has a central responsibility for a climate-neutral and sustainable transformation.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 4","pages":"114 - 120"},"PeriodicalIF":0.0,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00212-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46264560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-31DOI: 10.1007/s40629-022-00214-9
Wolfgang Pfützner
Summary
In addition to the therapeutic agent, drugs contain excipients such as stabilizers, preservatives, solubilizers, or dyes, some of which are identical to additives in foods. Anaphylaxis to these excipients is probably an underestimated problem. After the first descriptions of anaphylactic reactions to drug excipients appeared more than 30 years ago, the number of corresponding reports has increased significantly over the years. However, a diagnostic gap exists in the clarification of drug allergic reactions when the index product is not known and/or is not available for testing. In the present work, individual excipients are presented as examples for which publications on anaphylaxis are available. Furthermore, the options of allergological testing both in vivo and in vitro are discussed. The pathogenesis of such reactions is still unresolved in many cases, and current concepts are briefly presented in the conclusion. With increasing knowledge about anaphylaxis to drug excipients, it is assumed that these can then be recognized more often and diagnostically clarified.
{"title":"Anaphylaxis to drug excipients","authors":"Wolfgang Pfützner","doi":"10.1007/s40629-022-00214-9","DOIUrl":"10.1007/s40629-022-00214-9","url":null,"abstract":"<div><h2>Summary</h2><div><p>In addition to the therapeutic agent, drugs contain excipients such as stabilizers, preservatives, solubilizers, or dyes, some of which are identical to additives in foods. Anaphylaxis to these excipients is probably an underestimated problem. After the first descriptions of anaphylactic reactions to drug excipients appeared more than 30 years ago, the number of corresponding reports has increased significantly over the years. However, a diagnostic gap exists in the clarification of drug allergic reactions when the index product is not known and/or is not available for testing. In the present work, individual excipients are presented as examples for which publications on anaphylaxis are available. Furthermore, the options of allergological testing both in vivo and in vitro are discussed. The pathogenesis of such reactions is still unresolved in many cases, and current concepts are briefly presented in the conclusion. With increasing knowledge about anaphylaxis to drug excipients, it is assumed that these can then be recognized more often and diagnostically clarified.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 5","pages":"137 - 140"},"PeriodicalIF":0.0,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00214-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49225585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-17DOI: 10.1007/s40629-022-00210-z
Katharina Zednik, Isabella Pali-Schöll PhD
Summary
Background
In a world with rapidly increasing urbanization and loss of closeness to nature and biodiversity, the question arises to what extent our environment influences the health of people and animals. Moreover, in recent decades, the prevalence of respiratory diseases such as asthma and allergies has risen sharply. In this context, a direct link between the health of people and their environment seems plausible.
Results
Recent studies indicate that spending time in and being in contact with natural environments such as green spaces and associated soils is highly relevant to the health of people and companion animals. Green spaces in the environment of homes and schools of children and adults could contribute to the reduction of asthma and allergies. Especially the number and the structure of green spaces seems to be crucial. Home gardens and regular contact with animals can also reduce the risk of asthmatic and allergic diseases. In contrast, the increasing number of gray areas (roads, highways, construction sites, etc.) is likely to increase the risk of asthma and allergies. In the case of blue areas (rivers, lakes, sea), no correlation with atopic diseases has been found so far.
Conclusion
Biodiverse green spaces, especially forests and meadows, may offer some protection against asthma and allergies. Contact with soil and ground also seems important for the diverse skin microbiome, especially in childhood, and thus presumably beneficial for the immune system. Therefore, people and man’s best friend, the dog, should spend sufficient time in green, biodiverse environments, despite—or perhaps because—of rapid urbanization. People should also actively create such biodiverse surroundings in their closer living environment. On a broader level, in the spirit of the One Health concept, those responsible for city planning and transportation must take these connections into account.
{"title":"One Health: areas in the living environment of people and animals and their effects on allergy and asthma","authors":"Katharina Zednik, Isabella Pali-Schöll PhD","doi":"10.1007/s40629-022-00210-z","DOIUrl":"10.1007/s40629-022-00210-z","url":null,"abstract":"<div><h2>Summary</h2><div><h3>Background</h3><p>In a world with rapidly increasing urbanization and loss of closeness to nature and biodiversity, the question arises to what extent our environment influences the health of people and animals. Moreover, in recent decades, the prevalence of respiratory diseases such as asthma and allergies has risen sharply. In this context, a direct link between the health of people and their environment seems plausible.</p><h3>Results</h3><p>Recent studies indicate that spending time in and being in contact with natural environments such as green spaces and associated soils is highly relevant to the health of people and companion animals. Green spaces in the environment of homes and schools of children and adults could contribute to the reduction of asthma and allergies. Especially the number and the structure of green spaces seems to be crucial. Home gardens and regular contact with animals can also reduce the risk of asthmatic and allergic diseases. In contrast, the increasing number of gray areas (roads, highways, construction sites, etc.) is likely to increase the risk of asthma and allergies. In the case of blue areas (rivers, lakes, sea), no correlation with atopic diseases has been found so far.</p><h3>Conclusion</h3><p>Biodiverse green spaces, especially forests and meadows, may offer some protection against asthma and allergies. Contact with soil and ground also seems important for the diverse skin microbiome, especially in childhood, and thus presumably beneficial for the immune system. Therefore, people and man’s best friend, the dog, should spend sufficient time in green, biodiverse environments, despite—or perhaps because—of rapid urbanization. People should also actively create such biodiverse surroundings in their closer living environment. On a broader level, in the spirit of the One Health concept, those responsible for city planning and transportation must take these connections into account.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 4","pages":"103 - 113"},"PeriodicalIF":0.0,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00210-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44256281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-17DOI: 10.1007/s40629-022-00208-7
Joachim Sennekamp, Emilia Lehmann, Marcus Joest
Summary
Background
The ranges of most human IgG antibodies against avian, microbial, and chemical antigens between their cut off values and their maximum values detected by IgG ImmunoCAP™ (Thermo Fisher Diagnostics, Freiburg, Germany) are not well known in pulmonary immune-mediated disorders. In addition, for many antigens it is not yet known how frequently their IgG antibodies appear in patients with these lung diseases. Therefore, we evaluated ranges and frequencies of these IgG antibodies.
Methods
The sera of 47,200 patients with suspected hypersensitivity pneumonitis (HP, extrinsic allergic alveolitis) or bronchopulmonary mycoses (mainly allergic bronchopulmonary aspergillosis [ABPA]), which were examined for 32 various IgG antibodies against birds, bacteria, molds, yeasts, and chemicals using the IgG ImmunoCAP™ assay, were evaluated retrospectively.
Results
We found a large spreading of the specific IgG ranges with maximum values from 26 mgA/l for Rhizopus nigricans up to 4640 mgA/l for pigeon. When the maximum values in the literature are also taken into account, the ranges of avian antibodies reach values up to 7280 mgA/l, the ranges of molds and yeasts up to 1707 mgA/l, of bacterial thermoactinomycetes up to 206 mgA/l, and of chemicals up to 139 mgA/l. The evaluated antibody ranges of the individual antigens can be used to decide whether a detected IgG antibody value is weakly, moderately or strongly positive. According to consistent evidence from numerous studies, a strongly positive antibody indicates HP or pulmonary mycosis more likely than a weakly positive antibody. It was found that the antigens of the highest maximum antibody levels—pigeon, budgerigar, parrot, Aspergillus fumigatus—are the causative agents of the most common immune-mediated lung diseases: bird breeder’s lung and pulmonary aspergillosis. Evaluation of the frequencies of eight major IgG antibodies of HP revealed the following rates: pigeon 28%, Aspergillus fumigatus 25%, budgerigar 23%, Penicillium chrysogenum 11%, Saccharopolyspora rectivirgula 7%, Acremonium kiliense 6%, Aureobasidium pullulans 5%, and Thermoactinomyces vulgaris 2%.
Conclusion
This study is the first to evaluate the ranges not only of avian and Aspergillus fumigatus antigens, as has been done up to now, but also of antibodies against 24 other environmental antigens. Quantification of IgG antibodies regarding their specific ranges can help to improve the serodiagnostics of immune-mediated lung diseases. In the lower ranges IgG antibodies are mainly physiological, while higher ranges correlate with the mentioned diseases as HP and ABPA/allergic bronchopulmonary mycoses (ABPM). The determined frequencies of the eight HP antibodies can be helpful in establishing HP screening tests.
{"title":"Improved IgG antibody diagnostics of hypersensitivity pneumonitis and pulmonary mycoses by means of newly evaluated serum antibody ranges and frequencies using IgG ImmunoCAP™","authors":"Joachim Sennekamp, Emilia Lehmann, Marcus Joest","doi":"10.1007/s40629-022-00208-7","DOIUrl":"10.1007/s40629-022-00208-7","url":null,"abstract":"<div><h2>Summary</h2><div><h3>Background</h3><p>The ranges of most human IgG antibodies against avian, microbial, and chemical antigens between their cut off values and their maximum values detected by IgG ImmunoCAP™ (Thermo Fisher Diagnostics, Freiburg, Germany) are not well known in pulmonary immune-mediated disorders. In addition, for many antigens it is not yet known how frequently their IgG antibodies appear in patients with these lung diseases. Therefore, we evaluated ranges and frequencies of these IgG antibodies.</p><h3>Methods</h3><p>The sera of 47,200 patients with suspected hypersensitivity pneumonitis (HP, extrinsic allergic alveolitis) or bronchopulmonary mycoses (mainly allergic bronchopulmonary aspergillosis [ABPA]), which were examined for 32 various IgG antibodies against birds, bacteria, molds, yeasts, and chemicals using the IgG ImmunoCAP™ assay, were evaluated retrospectively.</p><h3>Results</h3><p>We found a large spreading of the specific IgG ranges with maximum values from 26 mgA/l for <i>Rhizopus nigricans</i> up to 4640 mgA/l for pigeon. When the maximum values in the literature are also taken into account, the ranges of avian antibodies reach values up to 7280 mgA/l, the ranges of molds and yeasts up to 1707 mgA/l, of bacterial thermoactinomycetes up to 206 mgA/l, and of chemicals up to 139 mgA/l. The evaluated antibody ranges of the individual antigens can be used to decide whether a detected IgG antibody value is weakly, moderately or strongly positive. According to consistent evidence from numerous studies, a strongly positive antibody indicates HP or pulmonary mycosis more likely than a weakly positive antibody. It was found that the antigens of the highest maximum antibody levels—pigeon, budgerigar, parrot, <i>Aspergillus fumigatus—</i>are the causative agents of the most common immune-mediated lung diseases: bird breeder’s lung and pulmonary aspergillosis. Evaluation of the frequencies of eight major IgG antibodies of HP revealed the following rates: pigeon 28%, <i>Aspergillus fumigatus</i> 25%, budgerigar 23%, <i>Penicillium chrysogenum</i> 11%, <i>Saccharopolyspora rectivirgula</i> 7%, <i>Acremonium kiliense</i> 6%, <i>Aureobasidium pullulans</i> 5%, and <i>Thermoactinomyces vulgaris</i> 2%.</p><h3>Conclusion</h3><p>This study is the first to evaluate the ranges not only of avian and <i>Aspergillus fumigatus</i> antigens, as has been done up to now, but also of antibodies against 24 other environmental antigens. Quantification of IgG antibodies regarding their specific ranges can help to improve the serodiagnostics of immune-mediated lung diseases. In the lower ranges IgG antibodies are mainly physiological, while higher ranges correlate with the mentioned diseases as HP and ABPA/allergic bronchopulmonary mycoses (ABPM). The determined frequencies of the eight HP antibodies can be helpful in establishing HP screening tests.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 6","pages":"172 - 182"},"PeriodicalIF":0.0,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00208-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47761545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-04DOI: 10.1007/s40629-022-00211-y
Duygu Yazici, Ismail Ogulur, Ozan Kucukkase, Manru Li, Arturo O. Rinaldi, Yagiz Pat, Alexandra Wallimann, Sebastian Wawrocki, Zeynep Celebi Sozener, Betul Buyuktiryaki, Cansin Sackesen, Mubeccel Akdis, Yasutaka Mitamura, Cezmi A. Akdis
The “epithelial barrier hypothesis” proposes that genetic predisposition to epithelial barrier damage, exposure to various epithelial barrier–damaging agents and chronic periepithelial inflammation are responsible for the development of allergic and autoimmune diseases. Particularly, the introduction of more than 200,000 new chemicals to our daily lives since the 1960s has played a major role in the pandemic increase of these diseases. The epithelial barrier constitutes the first line of physical, chemical, and immunological defence against external factors. A leaky epithelial barrier initiates the translocation of the microbiome from the surface of affected tissues to interepithelial and even deeper subepithelial areas. In tissues with a defective epithelial barrier, colonization of opportunistic pathogens, decreased microbiota biodiversity, local inflammation, and impaired regeneration and remodelling takes place. A dysregulated immune response against commensals and opportunistic pathogens starts. Migration of inflammatory cells to other tissues and their contribution to tissue injury and inflammation in the affected tissues are key events in the development and exacerbation of many chronic inflammatory diseases. Understanding the underlying factors that affect the integrity of epithelial barriers is essential to find preventive measures or effective treatments to restore its function. The aim of this review is to assess the origins of allergic and autoimmune diseases within the framework of the epithelial barrier hypothesis.
{"title":"Epithelial barrier hypothesis and the development of allergic and autoimmune diseases","authors":"Duygu Yazici, Ismail Ogulur, Ozan Kucukkase, Manru Li, Arturo O. Rinaldi, Yagiz Pat, Alexandra Wallimann, Sebastian Wawrocki, Zeynep Celebi Sozener, Betul Buyuktiryaki, Cansin Sackesen, Mubeccel Akdis, Yasutaka Mitamura, Cezmi A. Akdis","doi":"10.1007/s40629-022-00211-y","DOIUrl":"10.1007/s40629-022-00211-y","url":null,"abstract":"<div><p>The “epithelial barrier hypothesis” proposes that genetic predisposition to epithelial barrier damage, exposure to various epithelial barrier–damaging agents and chronic periepithelial inflammation are responsible for the development of allergic and autoimmune diseases. Particularly, the introduction of more than 200,000 new chemicals to our daily lives since the 1960s has played a major role in the pandemic increase of these diseases. The epithelial barrier constitutes the first line of physical, chemical, and immunological defence against external factors. A leaky epithelial barrier initiates the translocation of the microbiome from the surface of affected tissues to interepithelial and even deeper subepithelial areas. In tissues with a defective epithelial barrier, colonization of opportunistic pathogens, decreased microbiota biodiversity, local inflammation, and impaired regeneration and remodelling takes place. A dysregulated immune response against commensals and opportunistic pathogens starts. Migration of inflammatory cells to other tissues and their contribution to tissue injury and inflammation in the affected tissues are key events in the development and exacerbation of many chronic inflammatory diseases. Understanding the underlying factors that affect the integrity of epithelial barriers is essential to find preventive measures or effective treatments to restore its function. The aim of this review is to assess the origins of allergic and autoimmune diseases within the framework of the epithelial barrier hypothesis.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 4","pages":"91 - 102"},"PeriodicalIF":0.0,"publicationDate":"2022-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00211-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43585794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-26DOI: 10.1007/s40629-022-00207-8
K. Blumchen MD, A. Fischl, T. Eiwegger, E. Hamelmann, L. Klimek, L. Lange, Z. Szepfalusi, C. Vogelberg, K. Beyer
The current management of a primary IgE-mediated peanut allergy consists of the two basic pillars “exposure prophylaxis” with avoidance of the allergen and “emergency therapy” with short-term treatment of an acute allergic reaction after accidental ingestion. Accidental reactions are common despite attempted avoidance. The severity of an allergic or even anaphylactic reaction after accidental ingestion is difficult to assess prior to reaction. In addition, reaction thresholds may vary depending on the accompanying augmentation factor. Therefore, every peanut allergic patient should receive individual dietary counseling as well as instructions for the use of the emergency kit and a structured patient education program (anaphylaxis group training), if necessary. For the first time, since fall 2021 a causal treatment option with a drug for oral immunotherapy will now be available for 4‑ to 17-year-old peanut-allergic children and adolescents. The oral immunotherapy with peanut protein as defatted powder of Arachis hypogaea L., semen (peanuts) leads to desensitization with a good efficacy record and an acceptable safety profile. Other treatment options with different therapeutic approaches are also under development and will probably expand the range for treatment in the coming years.
{"title":"White paper peanut allergy","authors":"K. Blumchen MD, A. Fischl, T. Eiwegger, E. Hamelmann, L. Klimek, L. Lange, Z. Szepfalusi, C. Vogelberg, K. Beyer","doi":"10.1007/s40629-022-00207-8","DOIUrl":"10.1007/s40629-022-00207-8","url":null,"abstract":"<div><p>The current management of a primary IgE-mediated peanut allergy consists of the two basic pillars “exposure prophylaxis” with avoidance of the allergen and “emergency therapy” with short-term treatment of an acute allergic reaction after accidental ingestion. Accidental reactions are common despite attempted avoidance. The severity of an allergic or even anaphylactic reaction after accidental ingestion is difficult to assess prior to reaction. In addition, reaction thresholds may vary depending on the accompanying augmentation factor. Therefore, every peanut allergic patient should receive individual dietary counseling as well as instructions for the use of the emergency kit and a structured patient education program (anaphylaxis group training), if necessary. For the first time, since fall 2021 a causal treatment option with a drug for oral immunotherapy will now be available for 4‑ to 17-year-old peanut-allergic children and adolescents. The oral immunotherapy with peanut protein as defatted powder of <i>Arachis hypogaea L., semen</i> (peanuts) leads to desensitization with a good efficacy record and an acceptable safety profile. Other treatment options with different therapeutic approaches are also under development and will probably expand the range for treatment in the coming years.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 3","pages":"69 - 80"},"PeriodicalIF":0.0,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00207-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41608476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-28DOI: 10.1007/s40629-022-00205-w
Mandy Cuevas, Marie-Luise Polk, Sven Becker, Tilman Huppertz, Jan Hagemann, Christoph Bergmann, Holger Wrede, Wolfgang Schlenter, Boris Haxel, Karl-Christian Bergmann, Ludger Klimek
Background
Storage mites are frequently found in our daily environment. Nevertheless, storage mite allergy is often neglected in allergological diagnostics and possible allergies requiring therapy are thus overlooked.
Methods
Recommendations for action are made based on a literature review from March 2021 to August 2021 in PubMed, Medline, and GoogleScholar.
Results
This review article provides an overview of the species of storage mites, sensitization rates in different countries and occupations, and co-sensitization rates to house dust mite. Recommendations for diagnosis as well as therapy are given. The importance of provocation testing as well as causal therapy by allergen immunotherapy (AIT) is presented.
Conclusion
The position paper gives recommendations for the diagnosis and therapy of allergic rhinitis in case of storage mite allergy. AIT is recommended in symptomatic allergy and proven storage mite allergy. Reliable detection by provocation testing is advised in this persistent allergy. The therapy should be carried out independently of the treatment of a possible house dust mite allergy.
{"title":"Rhinitis allergica in storage mite allergy","authors":"Mandy Cuevas, Marie-Luise Polk, Sven Becker, Tilman Huppertz, Jan Hagemann, Christoph Bergmann, Holger Wrede, Wolfgang Schlenter, Boris Haxel, Karl-Christian Bergmann, Ludger Klimek","doi":"10.1007/s40629-022-00205-w","DOIUrl":"10.1007/s40629-022-00205-w","url":null,"abstract":"<div><h3>Background</h3><p>Storage mites are frequently found in our daily environment. Nevertheless, storage mite allergy is often neglected in allergological diagnostics and possible allergies requiring therapy are thus overlooked.</p><h3>Methods</h3><p>Recommendations for action are made based on a literature review from March 2021 to August 2021 in PubMed, Medline, and GoogleScholar.</p><h3>Results</h3><p>This review article provides an overview of the species of storage mites, sensitization rates in different countries and occupations, and co-sensitization rates to house dust mite. Recommendations for diagnosis as well as therapy are given. The importance of provocation testing as well as causal therapy by allergen immunotherapy (AIT) is presented.</p><h3>Conclusion</h3><p>The position paper gives recommendations for the diagnosis and therapy of allergic rhinitis in case of storage mite allergy. AIT is recommended in symptomatic allergy and proven storage mite allergy. Reliable detection by provocation testing is advised in this persistent allergy. The therapy should be carried out independently of the treatment of a possible house dust mite allergy.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 3","pages":"59 - 68"},"PeriodicalIF":0.0,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00205-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44330978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号